Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY24 results · Jul–Sep 2023
Aarti Drugs reported revenue from operations of ₹641.54 crore (down 6.7% from Q2 FY23) and net profit of ₹39.60 crore (up 2.2% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 641.54 | 687.72 | −6.7% | 661.11 | −3.0% |
| Other income | 0.68 | 0.05 | 14x | 0.60 | +13.3% |
| Total income | 642.22 | 687.77 | −6.6% | 661.71 | −2.9% |
| Profit before tax | 56.27 | 53.19 | +5.8% | 63.53 | −11.4% |
| Net profit for the period | 39.60 | 38.74 | +2.2% | 47.97 | −17.4% |
| Attributable to shareholders of the company | 39.59 | 38.75 | +2.2% | — | — |
| EPS, basic (₹) | 4.29 | 4.18 | +2.6% | 5.18 | −17.2% |
| Net margin (%) | 6.2 | 5.6 | 7.3 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 577.54 | 624.83 | −7.6% | 591.63 | −2.4% |
| Other income | 0.74 | 0.09 | +722.2% | 0.65 | +13.8% |
| Total income | 578.28 | 624.92 | −7.5% | 592.28 | −2.4% |
| Profit before tax | 46.83 | 50.08 | −6.5% | 53.04 | −11.7% |
| Net profit for the period | 34.58 | 36.58 | −5.5% | 39.54 | −12.5% |
| EPS, basic (₹) | 3.75 | 3.95 | −5.1% | 4.27 | −12.2% |
| Net margin (%) | 6.0 | 5.9 | 6.7 |
Consolidated
- Filed with BSE
- 21 Oct 2023, 17:15 IST
- Board meeting
- 19 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Oct 2023, 17:15 IST
- Board meeting
- 19 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Audited
- Source
- XBRL filing on BSE